MAGE-A4 IHC 1F9 pharmDx
Agilent Technologies, Inc. · Decision date Sep 15, 2026
What did the FDA approve?
FDA records P230016/S003 as a supplement to PMA P230016, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Sep 15, 2026.
FDA approval order statement
MAGE-A4 IHC IF9 pharmDx is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-MAGE-A4, Clone OTI1F9, intended for use in the detection of MAGE-A4 protein in formalin-fixed, paraffin-embedded (FFPE) synovial sarcoma tissue using the EnVision FLEX visualization system on Autostainer Link 48. MAGE-A4 protein expression in synovial sarcoma is determined by using the MAGE-A4 Tumor Intensity Proportion Score (TIPS), which is the overall percentage of viable tumor cells showing MAGE-A4 nuclear and/or cytoplasmic staining at staining intensity = 2+. The specimen should be considered positive if MAGE-A4 TIPS (= 2+) is = 75%.MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying patients with synovial sarcoma for whom TECELRA (afamitresgene autoleucel), a MAGE-A4-directed genetically modified autologous T-cell immunotherapy, is being considered.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Sep 15, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230016/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- Decision code
- APPR
- Decision date
- Sep 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230016 · Original PMA
MAGE-A4 IHC 1F9 pharmDx
P230016/S003 received
Application receipt date recorded by FDA.
P230016/S005 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
P230016/S003 · FDA decision
Normal 180 Day Track
P230016/S004 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MAGE-A4 IHC 1F9 pharmDxP230016 | Agilent Technologies, Inc. | PMA approval | Aug 1, 2024 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S005 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S004 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6392 Via Real, Carpinteria, CA, 93013
Sources and methodology
- Original FDA record: P230016/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

